Sign in

VIVS on Nasdaq

VivoSim Labs, INC.

American biological products company, incorporated in Delaware1

In its 2026 annual report the company says: “VivoSim Labs, Inc., is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional human tissue models of liver and intestine. We offer partners liver and intestinal toxicology insights using our new approach methodologies models. We also expect to offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.”4 It is headquartered in San Diego, California.1 Its shares trade on Nasdaq under the symbol VIVS.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$131.0KRevenue, fiscal 20262
-$13.8MNet income, fiscal 20262

Compare with Candel Therapeutics, Instil Bio, Inc. or Zivo Bioscience, Inc., or pick any stock.

  • TickerVIVS on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersSan Diego, California1
  • Incorporated inDE3
  • Business address11555 Sorrento Valley Road, Suite 100, San Diego, Ca 921213
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

VivoSim Labs, Inc. ("VivoSim," “we,” “us,” “our,” the “Company” and “our Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. We offer partners liver and intestinal toxicology insights using our new approach methodologies ("NAM") models. We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration ("FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. We also expect to offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-8768.7%Operating margin2
-10567.2%Net margin2
-9.0%Revenue growth, 20262
-$10.8MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Research and development36¢$4.2M
  • Selling, general and admin64¢$7.4M
  • Income tax0¢$2.0K

Out of $131.0K in revenue.2 The company lost money this year.

Financial statements

Revenue56789102$131.0K in 2026−96% since 2019
0$1.0M$2.0M$3.0M$4.0M2019: $3.1M$3.1M20192020: $2.2M$2.2M2020−29%2021: $0$020212022: $1.5M$1.5M20222023: $370.0K$370.0K2023−75%2024: $109.0K$109.0K2024−71%2025: $144.0K$144.0K2025+32%2026: $131.0K$131.0K2026−9%
Operating income56789102-$11.5M in 2026−58% since 2019
-$30.0M-$20.0M-$10.0M02019: -$27.3M-$27.3M20192020: -$21.5M-$21.5M2020−21%2021: -$16.8M-$16.8M2021−22%2022: -$11.5M-$11.5M2022−32%2023: -$17.7M-$17.7M2023+54%2024: -$15.1M-$15.1M2024−15%2025: -$12.6M-$12.6M2025−16%2026: -$11.5M-$11.5M2026−9%
Net income56789102-$13.8M in 2026−48% since 2019
-$30.0M-$20.0M-$10.0M02019: -$26.6M-$26.6M20192020: -$18.7M-$18.7M2020−30%2021: -$16.8M-$16.8M2021−10%2022: -$11.4M-$11.4M2022−32%2023: -$17.3M-$17.3M2023+51%2024: -$14.7M-$14.7M2024−15%2025: -$2.5M-$2.5M2025−83%2026: -$13.8M-$13.8M2026+456%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2026-03-312025-03-31
Total Revenues$131.0K$144.0K
Cost of revenues$0$5.0K
Research and development expenses$4.2M$5.0M
Selling, general, and administrative expenses$7.4M$7.7M
Total costs and expenses$11.6M$12.8M
Loss from Operations-$11.5M-$12.6M
Loss on issuance of common stock-$2.7M$0
Gain on investment in equity securities$94.0K$0
Gain on sale of asset$0$10.0M
Interest income$267.0K$140.0K
Interest expense-$12.0K-$10.0K
Total Other Income (Expense)-$2.4M$10.1M
Income Tax Expense-$2.0K-$2.0K
Net Loss-$13.8M-$2.5M
Comprehensive Loss-$13.8M-$2.5M
Net loss per common share basic-$5.35-$1.70
Net loss per common share diluted-$5.35-$1.70
Weighted average shares used in computing net loss per common share basic2.6M shares1.5M shares
Weighted average shares used in computing net loss per common share diluted2.6M shares1.5M shares

Compare VivoSim Labs, INC. with another company

Corporate structure

VivoSim Labs, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of VivoSim Labs, INC.

  • VivoSim Labs, INC. San Diego, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What VivoSim Labs, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$1.6M2 Mar 31, 2026$1.6M2 Mar 31, 20250%
Furniture and fixtures$66.0K2 Mar 31, 2026$66.0K2 Mar 31, 20250%
Computer equipment and software$244.0K2 Mar 31, 2026$244.0K2 Mar 31, 20250%
Property and equipment, before depreciation$1.9M2 Mar 31, 2026$1.9M2 Mar 31, 20250%
Accumulated depreciation$1.7M2 Mar 31, 2026$1.5M2 Mar 31, 2025+14.0%
Property and equipment, net$206.0K2 Mar 31, 2026$419.0K2 Mar 31, 2025−50.8%
Operating-lease assets (leased space)$407.0K2 Mar 31, 2026$867.0K2 Mar 31, 2025−53.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.0M2 Mar 31, 2026$11.3M2 Mar 31, 2025−55.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$010 Mar 31, 2025$297.0K10 Mar 31, 2024−100.0%

Properties, in its own words

In November 2020, we entered into a sixty-two month lease agreement for our long term permanent premises, consisting of approximately 8,051 square feet of lab and office space. In November 2021, we amended the permanent lease agreement to add an additional 2,892 square feet of office space in the same building. In December 2021, we took occupancy of the aforementioned lab and office space, located at 11555 Sorrento Valley Road, San Diego, CA 92121. See “Note 7. Leases” of the Notes to the Consolidated Financial Statements contained within this Annual Report for a further discussion of properties. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.

Item 2 of the 10-K filed Jul 14, 2026.4

Leadership

Who has led VivoSim Labs, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Keith Murphy2012–2017
  2. Taylor Crouch2017–2020

Chair

  1. Keith Murphy2012–now

President

  1. Keith Murphy2012–2017
  2. Taylor Crouch2017–2020
  3. Chris Heberlig2020

Chief financial officer

  1. Barry D. Michaels2012–2016
  2. Craig Kussman2016–2020
  3. Chris Heberlig2020
201520202025
Board members and other officers (25)

Former names

  • ORGANOVO HOLDINGS, INC.Jan 4, 2012 to Apr 23, 20253
  • REAL ESTATE RESTORATION & RENTAL, INC.Aug 4, 2010 to Oct 31, 20113

Timeline

  1. Oct 6, 20268-K Executive or director change; Shareholder vote43
  2. Aug 21, 20268-K Listing notice or transfer44
  3. Aug 6, 20268-K Results of operations45
  4. Jul 30, 20268-K Director nominations; Other events46
  5. Jul 24, 20268-K Listing notice or transfer; Other events47
  6. Jul 17, 20268-K Entered a material agreement; Unregistered sale of shares; Other events48
  7. Apr 3, 20268-K Entered a material agreement; Other events49
  8. Dec 18, 20258-K Shareholder vote50
  9. Aug 14, 20258-K Executive or director change; Regulation FD disclosure51
  10. May 6, 20258-K Other events52
  11. Apr 24, 20258-K Bylaws or fiscal year changed; Regulation FD disclosure; Other events53
  12. Apr 23, 20258-K Regulation FD disclosure54
  13. Apr 24, 2017New chief executive Taylor Crouch becomes CEO14
  14. Mar 13, 2012New chief executive Keith Murphy becomes CEO15

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/202655

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results45
  2. Apr 2, 2025Reported quarterly or annual results56

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

186 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 43 major events, 44 insider forms, 12 large holders, 64 other. The latest 20:

  1. Oct 6, 20268-K EDGAR
  2. Sep 1, 20264 EDGAR
  3. Aug 21, 2026ARS EDGAR
  4. Aug 21, 20268-K EDGAR
  5. Aug 21, 2026DEF 14A EDGAR
  6. Aug 17, 2026SCHEDULE 13G/A EDGAR
  7. Aug 13, 2026PRER14A EDGAR
  8. Aug 12, 202610-Q EDGAR
  9. Aug 10, 2026EFFECT EDGAR
  10. Aug 10, 2026PRE 14A EDGAR
  11. Aug 6, 20268-K EDGAR
  12. Jul 31, 2026S-1 EDGAR
  13. Jul 30, 20268-K EDGAR
  14. Jul 24, 20268-K CURRENT REPORT EDGAR
  15. Jul 17, 20268-K EDGAR
  16. Jul 14, 202610-K EDGAR
  17. Jun 29, 2026NT 10-K EDGAR
  18. Apr 6, 2026SCHEDULE 13G EDGAR
  19. Apr 3, 20268-K EDGAR
  20. Apr 2, 2026424B4 PROSPECTUS EDGAR

The 186 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 1 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 31, 2026Lialin Tony SergeChief Commercial OfficerBuy10,000$0.28$2.8KForm 4
Nov 17, 2025Gobel DavidDirectorSale3,266$2.24$7.3KForm 4
Nov 15, 2023Gobel DavidDirectorSale19,607$1.62$31.8KForm 4
Nov 19, 2021Gobel DavidDirectorSale145$5.29$767Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2026Keith Murphy54$740.2K$866.0K62
2026Tony LialinChief Commercial Officer55$221.5K$298.0K62
2026Amar SethiChief Scientific Officer55$117.7K$235.3K62
2026Norman Staskey55$119.5K62
2025Executive Chairman$726.7K$1.2M62
2025Chief Financial Officer$20.9K62

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Geode Capital Management, LLC25,976$27.8K0.0%−10,874
Renaissance Technologies LLC18,500$19.8K0.0%New
Vanguard Capital Management LLC15,371$16.4K0.0%No change
BlackRock, Inc.11,817$12.6K0.0%No change
Vanguard Fiduciary Trust Co7,003$7.5K0.0%No change
Tower Research Capital LLC (TRC)5,249$5.6K0.0%+2,941
SBI Securities Co., Ltd.221$2360.0%No change
Larson Financial Group LLC166$1780.0%No change
Albion Financial Group /ut159$1710.0%No change
Wells Fargo & Company/mn111$1190.0%No change
Osaic Holdings, Inc.84$880.0%−11
Morgan Stanley49$520.0%−1
UBS Group AG18$200.0%−934
Hrt Financial LP18,319$190.0%New
Caitong International Asset Management Co., Ltd17$180.0%+14
IFG Advisory, LLC14$150.0%New
Integrated Wealth Concepts LLC8$90.0%New
Rockefeller Capital Management L.P.2$20.0%No change
Golden State Wealth Management, LLC2$20.0%No change
Activest Wealth Management2$20.0%No change
Federation des caisses Desjardins du Quebec2$20.0%No change
Harbour Investments, Inc.1$10.0%No change
First Command Advisory Services, Inc.1$10.0%No change
Hilton Head Capital Partners, LLC1$10.0%No change
Royal Bank Of Canada1$00.0%−1

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How VivoSim Labs, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARVivoSim Labs, INC.1
  • CIK0001497253
  • Employer ID (EIN)27-14889434
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsMarch 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address11555 Sorrento Valley Road, Suite 100, San Diego, CA 921211
  • Phone858-224-10001
  • Shares outstanding14,850,612 as of Aug 10, 202613
  • Public float$7.5M as of Sep 30, 20254
  • AuditorRosenberg Rich Baker Berman, P.A., Somerset, New Jersey PCAOB ID 894
  • On EDGAR sinceAug 4, 20101
  • Filings818 in all: 4 (258), 8-K (186), 10-Q (46), 3 (36), CORRESP (25), SC 13G/A (22), DEFA14A (20), UPLOAD (17)1
    All 53 form types

    10-K (15), 424B5 (15), 425 (15), DEF 14A (15), EFFECT (14), S-8 (12), S-1/A (9), SC 13G (9), 5 (8), CT ORDER (7), 8-K/A (6), PRE 14A (6), S-1 (6), 10-K/A (5), 424B3 (5), S-3 (5), S-8 POS (5), ARS (4), SC TO-I/A (4), 424B4 (3), D (3), NT 10-K (3), POS AM (3), S-4/A (3), SCHEDULE 13G/A (3), 3/A (2), 4/A (2), 8-A12B (2), PX14A6G (2), SEC STAFF LETTER (2), 10-KT (1), 144 (1), 25 (1), 8-A12G (1), CERTNAS (1), CERTNYS (1), D/A (1), DEFR14A (1), DRS (1), NT 10-Q (1), PRER14A (1), RW (1), S-4 (1), SC TO-I (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Jul 14, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) Aug 21, 2026
    Latest 8-K (8-K) Oct 6, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareVIVSNasdaq

From the cover page of the 10-K filed Jul 14, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks VivoSim Labs, INC. names in Item 1A of its 10-K filed Jul 14, 2026: 51 risks under these headings, as written.4

  • We will incur substantial additional operating losses over the next several years as our services and research and development activities proceed.
  • Using our platform technology to develop healthy human tissues and disease models to support both external and internal drug discovery and development is new and unproven.
  • We will require access to a constant, steady, reliable supply of human cells to support our services and research and development activities.
  • We may require substantial additional funding. Raising additional capital would cause dilution to our existing stockholders and may restrict our operations or require us to relinquish rights to our technologies or to a product candidate.
  • We will be supporting external clinical development through our services and pursuing our own R&D programs. Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future results.
  • The near and long-term viability of our services and R&D efforts will depend on our ability to successfully establish strategic relationships.
  • Current and future legislation may increase the difficulty and cost of commercializing drug candidates and may affect the prices that can be charged if drug candidates are approved for commercialization.
  • Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern. Separately, our independent registered public accounting firm has included in its opinion for the year ended March 31, 2026 an explanatory paragraph expressing substantial doubt in our ability to continue as a going concern, which may hinder our ability to obtain future financing.
  • We have a history of operating losses and expect to incur significant additional operating losses.
  • There is no assurance that an active market in our common stock will continue at present levels or increase in the future.
  • The price of our common stock may continue to be volatile, which could lead to losses by investors and costly securities litigation.
  • Patents covering our products could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.
The other 39 risks
  • We may be involved in lawsuits or other proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
  • Risks Related to our Business
  • We are a pharmaceutical and biotechnology services company focusing on providing testing of drugs and drug candidates in 3D human tissue models, which is an unproven business strategy that may never achieve profitability.
  • We will face intense competition in our services and drug discovery efforts.
  • Our business will be adversely impacted if we are unable to successfully attract, hire and integrate key additional employees or contractors.
  • We will be supporting external clinical development by third parties through our services and pursuing our own R&D programs. Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future results.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on potential product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • We will rely upon third-party contractors and service providers for the execution of critical aspects of any future development programs. Failure of these collaborators to provide services of a suitable quality and within acceptable timeframes may cause the delay or failure of any future development programs.
  • The near and long-term viability of our services platform and R&D efforts will depend on our ability to successfully establish strategic relationships.
  • Our ability to effectively monitor and respond to the rapid and evolving developments and expectations relating to sustainability, including environmental, social and governance factors may impose unexpected costs or results in reputational or other harm that could have a material adverse effect on our business.
  • Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.
  • Our use of generative artificial intelligence tools in our operations may expose us to risks related to confidentiality, accuracy, regulatory compliance and intellectual property ownership or rights.
  • Risks Related to Government Regulation
  • In the past, we have used hazardous chemicals, biological materials and infectious agents in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.
  • If we fail to obtain and sustain an adequate level of reimbursement for our potential products by third-party payors, potential future sales would be materially adversely affected.
  • Changes in government funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, properly administer drug innovation, or prevent our potential product candidates from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business, financial condition and results of operations.
  • Risks Related to Our Capital Requirements, Finances and Operations
  • Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern. Separately, our independent registered public accounting firm has included in its opinion for the year ended March 31,
  • 2026 an explanatory paragraph expressing substantial doubt in our ability to continue as a going concern, which may hinder our ability to obtain future financing.
  • Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to curtail or cease our operations.
  • Our quarterly operating results may vary, which could negatively affect the market price of our common stock.
  • We may identify material weaknesses in our internal control over financial reporting in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements.
  • The anticipated benefits of the sale of our FXR program may not be fully realized as we may not receive some or all of the potential milestone payments related to the sale of our FXR program.
  • Future strategic investments could negatively affect our business, financial condition and results of operations if we fail to achieve the desired returns on our investment.
  • Our business could be adversely impacted if we are unable to retain our executive officers and other key personnel.
  • We may be subject to security breaches or other cybersecurity incidents that could compromise our information and expose us to liability.
  • Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition and results of operations.
  • We and our partners may be subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security, and changes in such laws, regulations, policies or how they are interpreted or changes in contractual obligations could adversely affect our business.
  • We may experience conflicts of interest with Viscient Biosciences, Inc. with respect to business opportunities and other matters.
  • Risks Related to Our Common Stock and Liquidity Risks
  • We could fail to maintain the listing of our common stock on the Nasdaq Capital Market, which could seriously harm the liquidity of our stock and our ability to raise capital or complete a strategic transaction.
  • Investors may experience dilution of their ownership interests because of the future issuance of additional shares of our capital stock.
  • We do not intend to pay dividends for the foreseeable future.
  • Anti-takeover provisions in our organizational documents and Delaware law may discourage or prevent a change of control, even if an acquisition would be beneficial to our stockholders, which could affect our stock price adversely and prevent attempts by our stockholders to replace or remove our current management.
  • Risks Related to Our Intellectual Property
  • If we are not able to adequately protect our proprietary rights, our business could be harmed.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We depend on license agreements with University of Missouri for rights to use certain patents, pending applications, and know how. Failure to comply with or maintain obligations under these agreements and any related or other termination of these agreements could materially harm our business and prevent us from developing or commercializing new product candidates.
  • We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • Risks Related to Litigation
  • Claims, litigation, government investigations and other proceedings may adversely affect our business, operating results and financial condition.
  • General Risk Factors
  • Compliance with the reporting requirements of federal securities laws can be expensive.
  • If we fail to comply with the rules of Section 404 of the Sarbanes-Oxley Act related to accounting controls and procedures, or, if we discover material weaknesses and deficiencies in our internal control and accounting procedures, we may be subject to sanctions by regulatory authorities and our stock price could decline.

Legal proceedings

In addition to commitments and obligations in the ordinary course of business, we may be subject, from time to time, to various claims and pending and potential legal actions arising out of the normal conduct of our business.

We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is subjective and requires judgments about future events. When evaluating contingencies, we may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against us may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of our potential liability.

See “Note 8. Commitments and Contingencies” of the Notes to the Consolidated Financial Statements contained within this Annual Report for a further discussion of potential commitments and contingencies related to legal proceedings.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62